EGFR and non-small cell lung carcinoma: In addition, EGFR inhibitors, particularly osimertinib, and immunotherapy, particularly pembrolizumab, are two targeted therapies that have the potential to improve outcomes of NSCLC patients in SSA if given as first-line.